

## **CLAIMS**

### **WHAT IS CLAIMED IS:**

1. A method for detecting a pathological cell in a patient, said method comprising detecting in a biological sample from said patient a nucleic acid or polypeptide comprising a sequence at least 80% identical to a sequence selected from SEQ ID NOs:1-116.  
5
2. The method of Claim 1, wherein said pathological cell has a pathology selected from those listed Table 1.
3. The method of Claim 1, wherein said biological sample is tissue from an organ which is affected by a pathology listed in Table 1.  
10
4. The method of Claim 1, wherein said nucleic acids are mRNA.
5. The method of Claim 1, further comprising a step of amplifying nucleic acids.
6. The method of Claim 1, wherein said nucleic acid comprises a sequence selected from SEQ ID NOs:1-58.  
15
7. The method of Claim 1, wherein said polypeptide comprises a sequence selected from SEQ ID NOs:59-116.
8. The method of Claim 1, wherein said detecting comprises using a biochip comprising a nucleic acid at least 80% identical to SEQ ID NOs:1-58.
9. The method of Claim 1, wherein said patient is undergoing a therapeutic regimen to treat a pathology selected from those listed Table 1.  
20
10. The method of Claim 1, wherein said patient is suspected of having a pathology selected from those listed Table 1.
11. An isolated nucleic acid molecule comprising a sequence selected from SEQ ID NOs: 1-58.  
25

12. The nucleic acid molecule of Claim 11, wherein the nucleic acid is labeled.
13. An expression vector comprising the nucleic acid of Claim 11.
14. A host cell comprising the expression vector of Claim 13.
15. An isolated nucleic acid encoding a polypeptide sequence selected from SEQ  
5 ID NOs: 59-116.
16. An isolated polypeptide encoded by a sequence selected from SEQ ID  
NOs:1-58.
17. An antibody that specifically binds a polypeptide of Claim 16.
18. The antibody of Claim 17, wherein the antibody is a humanized antibody.
- 10 19. The antibody of Claim 17, wherein the antibody is an antibody fragment.
20. The antibody of Claim 17, wherein the antibody is conjugated to an effector  
component.
21. The antibody of Claim 17, wherein the antibody is conjugated to a detectable  
label or a cytotoxic chemical.
- 15 22. A method for specifically targeting a compound to a pathological cell in a  
patient, said method comprising administering to said patient an antibody of Claim 17,  
wherein said antibody is conjugated to the compound.
23. A method for detecting a pathological cell in a patient, said method  
comprising contacting a biological sample with an antibody of Claim 17.
- 20 24. The method of Claim 22, wherein said antibody is conjugated to an effector  
component or a fluorescent label.
25. The method of Claim 22, wherein said said biological sample is a blood,  
serum, urine, or stool sample.

26. A method for identifying a compound that modulates a pathology-associated polypeptide, said method comprising:

- a) contacting said compound with a pathology-associated polypeptide, said polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to SEQ ID NOs:1-58; and
- b) determining the effect of said compound upon the function of said polypeptide.

27. A screening assay comprising:

- a) administering a test compound to a cell from a mammal exhibiting a pathology selected from those listed in Table 1;
- b) administering a test compound to a cell from a mammal not exhibiting said pathology;
- c) comparing the expression level of a polynucleotide of the cell comprising a sequence at least 80% identical to SEQ ID NOs:1-58 with the expression level of said polynucleotide of a control cell;

whereby modulation of the expression level of the polynucleotide of the cell indicates that the test compound is a drug candidate.